Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAS: Letrozole and hCG for AAS-induced Hypogonadism
NCT05205837Phase 4Terminated
- Sponsor
- Rigshospitalet
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of letrozole and human chorionic gonadotropin in Hypogonadism (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in plasma total testosterone concentration at 24 weeks. Started Nov 2021; status: terminated.
02
Drugs
letrozolehuman chorionic gonadotropin
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT05205837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205837.